Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer

2026-05-13
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

2026-05-13
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026...

AngioDynamics Files Patent Infringement Lawsuit Against Endovascular Engineering On April 23, 2026; Seeks Damages And Equitable Relief In Lawsuit Against Endovascular Engineering

2026-04-23
-SEC Filing

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

2026-04-06
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.

AngioDynamics Growing, But With More Noise Than The Street Likes

2026-04-05
AngioDynamics' Med Tech business continues to show robust growth, but margins and legacy Medical Devices drag on valuation. Read why I rate ANGO stock a Buy.

AngioDynamics shares are trading lower. The company reported Q3 financial results and updated its FY26 guidance.

2026-04-02

AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance

2026-04-02
AngioDynamics Q3 2026 results beat EPS estimates and raised full-year guidance, driven by strong 19% growth in its Med Tech portfolio.

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

2026-04-02
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call April 2, 2026 8:00 AM EDTCompany ParticipantsJames Clemmer - CEO, President & DirectorStephen...

AngioDynamics, Inc. 2026 Q3 - Results - Earnings Call Presentation

2026-04-02
2026-04-02. The following slide deck was published by AngioDynamics, Inc.

Earnings Scheduled For April 2, 2026

2026-04-02